Results 81 to 90 of about 26,025 (223)
Small molecules, big targets: drug discovery faces the protein-protein interaction challenge. [PDF]
, 2016 Protein-protein interactions (PPIs) are of pivotal importance in the regulation of biological systems and are consequently implicated in the development of disease states.A Ciulli, A Degterev, A Oberstein, A Patel, A Patel, A Shaginian, A Turnbull, A Winter, AA Bogan, AA Lugovskoy, AB Mahon, AC Braisted, AD Morley, AF Donnell, AG Coyne, AJ Souers, AL Jochim, AM Petros, AM Petros, Andrew R. Bayly, AP Higueruelo, AR Bayly, AV Follis, B Ku, B Lehner, B Ma, B Padmanabhan, BC Raimundo, BE Sleebs, BL Grasberger, C Tse, C Zhuang, CA Lepre, CD Thanos, CG Wilson, CH Arrowsmith, CH Kenny, Chris Abell, CQ Wei, CQ Wei, D Cox, D Grimme, D Marcotte, D Rognan, D Seebach, D Szklarczyk, DA Erlanson, DC Fry, DE Scott, DE Scott, DI Hammoudeh, DJ Craik, DJ Huggins, DK Johnson, Duncan E. Scott, EF Lee, EF Lee, EF Lee, F Christ, F Cossu, F Falchi, FB Sheinerman, FP Davis, G Wang, G Zimmermann, GR Bickerton, H Jhoti, H Jubb, H Karatas, H Sun, H Wu, H Yin, H Zhou, HL Perez, HP Sun, HY Sun, I Monfardini, I Navratilova, I Van Molle, IJ Enyedy, J Hyde, J Liu, JA Kritzer, JA Wells, JB Baell, JC Fuller, JD Sadowsky, JG Allen, JL Wang, JM Davis, John Skidmore, JW Huang, JW Tilley, K Sauve, KI Tong, L Chen, L Hu, L Pellegrini, LD Walensky, LD Walensky, LK Henchey, LM Meireles, LT Vassilev, M Bruncko, M Rickert, M Sattler, M Vogler, M Whittaker, MC Lo, MC Smith, MD Wendt, MJ Basse, MJ de Vega, ML Stewart, MR Arkin, MR Arkin, N Sugaya, O Ichihara, O Keskin, O Keskin, O Mirguet, P Chakrabarti, P Filippakopoulos, P Filippakopoulos, P Mukherjee, P Sledz, P Walter, PJ Hajduk, PJ Hajduk, PJ Real, PW White, Q Cai, Q Chu, QC Zhang, R Hancock, R Hancock, RF Kester, RJ Bienstock, RJ Robb, S Barelier, S Ducki, S Ferrari, S Fletcher, S Fletcher, S Jones, S Miller, SC Lo, SD Furdas, SM Biros, SM Srinivasula, SP Brown, T Clackson, TA Larsen, TG Davies, TJ Blackburn, TK Oost, TL Blundell, TL Blundell, TS Peat, VS Rao, W Antuch, WA Loughlin, WB Turnbull, X Morelli, XQ Liu, Y Chen, Y Huang, Y Tanaka, Y Zhao, YS Tan, Z Hu, ZY Jiang +171 morecore +2 more sourcesImproved survival with fludarabine‐based therapies in mixed phenotype acute leukaemia: A population‐based study using the WHO 2022 classification
British Journal of Haematology, EarlyView.Summary
Mixed phenotype acute leukaemia (MPAL) is a rare subtype of acute leukaemia possessing significant therapeutic challenges, as no standardized, evidence‐based treatment regimen has been defined. In this nationwide study, we aimed to assess the effect of an acute lymphoid leukaemia (ALL)‐like regimen; an acute myeloid leukaemia (AML)‐like regimen;Lisa‐Maj Christensen, Mikkel Runason Simonsen, Jonas Faartoft Jensen, Daniel Tuyet Kristensen, Karen Dybkær, Kirsten Grønbæk, Tarec Christoffer El‐Galaly, Marianne Schmidt Ettrup, Hans Beier Ommen, Anne Louise Tølbøll Sørensen, Dennis Lund Hansen, Marianne Tang Severinsen +11 morewiley +1 more sourceThe oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed/refractory acute myeloid leukemia
Blood Neoplasia: The antiapoptotic protein myeloid cell leukemia 1 (Mcl-1) promotes cell survival in acute myeloid leukemia (AML), and its overexpression is associated with resistance to venetoclax.Yesid Alvarado-Valero, Rachel J. Cook, Shira N. Dinner, Michael Keng, Kebede H. Begna, Nathalie Javidi-Sharifi, Sameem Abedin, Monzr M. Al Malki, Vijaya Raj Bhatt, Prabhu Rajagopalan, Min Tang, Sandra E. Wiley, Richard G. Ghalie, Matthew S. Davids +13 moredoaj +1 more sourceReal‐world treatment patterns and outcomes in accelerated and blast‐phase myeloproliferative neoplasms: Insights from a large multi‐centre cohort analysis in the United Kingdom
British Journal of Haematology, EarlyView.Summary
This UK‐based retrospective analysis describes real‐world treatment patterns and outcomes in 175 patients with accelerated (AP, n = 69) or blast‐phase (BP, n = 106) ‘Philadelphia‐negative’ myeloproliferative neoplasms (MPN‐AP/BP) diagnosed between 2013 and 2025. Median age at transformation was 71 years.Alexandros Rampotas, Gabriel Naylor‐Layland, Clare Brown, Ahmad Alabdulkarim, Jennifer Ryan, Frances Wadelin, Samah Alimam, Phyo Wint Wint Tun, Jonathan Lambert, Jennifer O'Sullivan, Andrew J. Wilson, Laith Tafesh, Andrew McGregor, Simone Claudiani, Andrew Innes, Emily Booth, James Leveson, Steve Knapper, Mamta Garg, Mani Dubey, Theodora Vatopoulou, Charlotte Brierley, Wai Ka Natalie Leung, Graham Greenfield, Mary Frances McMullin, Alesia Khan, Kate Milne, Duncan Brian, Anna Godfrey, Claire N. Harrison, Bethan Psaila, Patrick Harrington, Amy Kirkwood, Tim C. P. Somervaille, Donal P. McLornan, on behalf of the UK Blood Cancer Research Network MPN Clinical Study Group +35 morewiley +1 more sourceClonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia
Nature Communications, 2018 BCL2-inhibitor venetoclax is used to treat relapsed/refractory chronic lymphocytic leukemia (CLL). Here, the authors show the clonal dynamics towards venetoclax resistance by performing whole-exome sequencing of 8 CLL patients undergoing venetoclax ...Carmen D. Herling, Nima Abedpour, Jonathan Weiss, Anna Schmitt, Ron Daniel Jachimowicz, Olaf Merkel, Maria Cartolano, Sebastian Oberbeck, Petra Mayer, Valeska Berg, Daniel Thomalla, Nadine Kutsch, Marius Stiefelhagen, Paula Cramer, Clemens-Martin Wendtner, Thorsten Persigehl, Andreas Saleh, Janine Altmüller, Peter Nürnberg, Christian Pallasch, Viktor Achter, Ulrich Lang, Barbara Eichhorst, Roberta Castiglione, Stephan C. Schäfer, Reinhard Büttner, Karl-Anton Kreuzer, Hans Christian Reinhardt, Michael Hallek, Lukas P. Frenzel, Martin Peifer +30 moredoaj +1 more sourcePredicting the cell death responsiveness and sensitization of glioma cells to TRAIL and temozolomide. [PDF]
, 2016 Genotoxic chemotherapy with temozolomide (TMZ) is a mainstay of treatment for glioblastoma (GBM); however, at best, TMZ provides only modest survival benefit to a subset of patients.Johnston, Grainne, Lincoln, Frank A, Murphy, Brona M, Noonan, Janis, Rehm, Markus, Weyhenmeyer, Birgit C, Würstle, Maximilian L +6 morecore +1 more sourceMultiplexed Transcriptomics for Screening Drug Combinations and Defining the Mechanism of Action of HCC Therapeutics at Single‐Cell Resolution
Cell Proliferation, EarlyView.We designed a framework for screening clinical drug combinations with anti‐hepatocellular carcinoma (HCC) activity, comprising four parts: primary screening, single‐cell screening, functional validation, and mechanism research. High‐throughput single‐cell screening identifies HY (HHT and YM155) as a potent anti‐HCC drug combination, validated by in ...Mengmeng Jiang, Haide Chen, Guoxia Wen, Yuqing Mei, Wenzhao Zhou, Bin Xu, Tingyue Zhang, Guangyan Li, Junqing Wu, Xiaoping Han, Xudong Fu, Guoji Guo, Jingjing Wang +12 morewiley +1 more sourceGilteritinib overcomes primary resistance to venetoclax in a patient with FLT3 wild-type refractory/relapsed AML: Case report and exploration of possible mechanisms
HeliyonVenetoclax, a selective BCL-2 inhibitor, has shown superior efficacy in the treatment of AML. Nevertheless, some AML patients with AML1-ETO respond poorly to venetoclax treatment.Man Li, Xiawan Yang, Yaonan Hong, Qi Liu, Yingying Shen, Tonglin Hu, Yiping Shen, Guoyin Kai, Dijiong Wu +8 moredoaj +1 more sourceMinimal residual disease is an independent predictor for 10-year survival in CLL [PDF]
, 2016 Minimal residual disease (MRD) negativity, defined as Abraham Varghese, Abrisqueta, Andy C. Rawstron, Bosch, Böttcher, Chi Doughty, Darren J. Newton, Dreger, Eichhorst, Fischer, Goede, Hallek, Landau, Ma, Marwan Kwok, Moreno, Moreton, Nadeu, Paul A. S. Evans, Paul Moreton, Peter Hillmen, Pettitt, Rawstron, Rawstron, Rawstron, Rossi, Santacruz, Sheila J. M. O’Connor, Strati, Thompson +29 morecore +1 more source
